Cointime

Cellectis

company

About

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.

Highlights

Stock Symbol
fra:ZVAA
Total Funding Amount
€57.40M $164M
Funding Rounds
7
Investors
6
Acquisition
2
Employee Profiles
3

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€40M
Industries
Biopharma,Biotechnology,Health Care,Medical
Founded date
Dec 1, 1999
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
fra:ZVAA
Legal Name
Cellectis SA

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers.

Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
€57.40M $164M
Cellectis has raised a total of €57.40M $164M in funding over 2 rounds. Their latest funding was raised on Dec 28, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 28, 2022 Post-IPO Debt €40M 1 European Investment Bank — Detail
Apr 11, 2018 Post-IPO Equity $164M — — — Detail
Jan 1, 2017 Post-IPO Equity — 1 — — Detail
Apr 17, 2015 IPO — — — — Detail
Jun 1, 2005 Series C €5.60M 4 — — Detail
Show More

Investors

Number of Lead Investors
Number of Investors
1
6
Cellectis is funded by 6 investors. European Investment Bank and 4BIO Capital are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Post-IPO Debt
4BIO Capital — Post-IPO Equity
Andera Partners — Series C
BankInvest Biomedical Venture — Series C
Idinvest Partners — Series C
ODYSSEE VENTURE — Series C

Employee Profiles

Number of Employee Profiles
3
Cellectis has 3 current employee profiles, including Employee Bing C Wang
Bing C Wang
Employee
Jon Voss
Executive
Andre Choulika
Executive

Acquisition

Cellectis has acquired 2 organizations. Their most recent acquisition was Cyto Pulse Sciences on Sep 9, 2010. They acquired Cyto Pulse Sciences for $2.20M.

Date Company Name
Industry Acquisition Type Price
Sep 9, 2010 Cyto Pulse Sciences
Health Care acquisition $ 2.20M Detail
Sep 15, 2011 Cellartis
Biotechnology acquisition — Detail
Cointime
İçerikler
Şirket.